Certain chemical and pharmacological properties of sodium nitroprusside, a cheap, readily available chemical, have been described. It is a powerful hypotensive agent when given intravenously to hypertensive patients. It is no more effective than the sodium thiocyanate into which it is converted when given by mouth. Prolonged infusion has proved highly effective in the treatment of hypertensive encephalopathy.
T HE EXPERIENCE of most physicians with sodium nitroprusside (Na2[Fe(CN)5(N0)] .2H20) is limited to its use in diagnostic tests for acetone, aldehydes, alkali sulfides and sulfur dioxide. It has been used in suicides only rarely, and curiously, only by medical and nursing personnel'; the proximate cause of death was believed to be cyanogen (prusside) formed by decomposition of nitroprusside (=Fe(CN)5NO). Hypodermically, the average lethal dose of nitroprusside in guinea pigs is 7.5 mg. and that of potassium cyanide is 1.9 mg. 2 The hypotensive action of parenteral nitroprusside has been given little attention other than by Johnson3 who described it as being 50 to 1000 times greater than that of the nitrite ion. He estimated the ratio between depressor and toxic dosages as 1:10. Its depressor effect resembled that of sodium nitrite in that it seemed to be due to decreased peripheral vascular resistance and was independent of innervation. Johnson did not believe the evidence supported the assertion that toxic effects of parenteral nitroprusside could be due to liberation of cyanogen.
This report includes additional data on the biochemistry and pharmacology of nitroprusside, as well as an evaluation of its place in the treatment of hypertensive disease.
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BIOCHEMICAL REACTIONS Nitroprusside decomposes with liberation of cyanogen when placed in contact with animal tissues.4 It reacts similarly when mixed with protein-free filtrates of blood, and this over a wide range of pH, so the reaction is not enzymatic.
Since the depressor action of nitroprusside might be associated with decomposition, this process was studied further by Dr. Merlin Bumpus of the Research Division of the Cleveland Clinic. The iron atom in nitroprusside is in the ferrous state and as well as cobalt is able to form complexes with sulfhydryl-containing amino acids.5 From this it seemed likely that the reaction depends on the interaction of sulfhydryl compounds in body fluids with the nitroprusside ion. This view was tested by incubating, in the manner described by Hill,4 aliquots of a solution of sodium nitroprusside with blood and with solutions of glycine, proline, methionine and cysteine. Neither glycine nor proline caused cyanogen to be liberated; some was detected in the methionine incubate and the cysteine incubate gave an amount which corresponded to that recovered from the mixture with blood.
This reaction was also examined by Dr. Carlos Monge C., who compared the release of mixture was incubated for 60 minutes at 38 C., during which time no release of cyanogen could be demonstrated. An equal volume of red cells was then added to the plasma and the incubation continued; the cyanogen released per milliliter of the original plasma was found to be about 0.6 micrograms at 45 minutes and 2.6 at the end of two hours. The latter yield is substantially complete. Incubation of nitroprusside with whole blood at 38 C. yielded complete recovery as cyanogen at about 90 minutes; recoveries at 10 The usual dose given to dogs anesthetized with pentobarbital was 2.5 micrograms per kilogram intravenously. The average fall in arterial pressure in 20 animals was 57 mm. Hg with a range of -20 to -80 mm. Hg. Heart rate and respiration were little changed unless the hypotension was severe when slight tachycardia occurred. Quite as often the heart rate slowed after nitroprusside. No rhythm change was noted. Repeated administration did not lead to tachyphylaxis nor to refractoriness when given at intervals of about 10 minutes.
Intravenous infusions of nitroprusside permitted blood pressure to be maintained almost indefinitely at any desired level by altering inflow rate. In the presence of hypotension elicited by infusion of nitroprusside, responses to a variety of intravenously injected vasoactive substances (noradrenaline, 1,1-dimethyl-4-phenylpiperazinium iodide-DMPP-vasopressin) were moderately depressed.
Effect showed a more rapid and prolonged rise in thiocyanate.
Signs and symptoms of toxicity closely resembled those following administration of potassium thiocyanate. Fatigue, nausea, loss of appetite, and weakness were the most common symptoms shown by most patients; other patients ran almost the entire gamut of symptoms, just as they do with thiocyanate. On two occasions, skin rashes due to thiocyanate required discontinuance of the drug. Headache associated with hypertensive disease often disappeared following nitroprusside but in two patients it became worse. Anemia may have been augmented in a few patients with renal failure but this is hard to prove in a disease characterized by anemia.
The effect on average arterial pressure after about six weeks administration was usually to cause a moderate (>20/15 mm. Hg) decrease. Decreases of this degree occurred in nine of 16 patients, and in those with malignant as well as essential hypertension; greater but transient decreases of arterial pressure were occasionally observed. In the remainder, the drug had no provable effect, even when administered for over a year. Nitroprusside placebo was used either before or after the drug itself. Often several months were required for the blood pressure to return to the control level on discontinuing the drug; on its return thiocyanate was given instead of nitroprusside to increase serum level of thiocyanate to that observed during administration of nitroprusside. A typical example is shown in fig. 1 , in which it will be seen that the blood pressure fell about equally with both drugs. We have been unable to distinguish between the fall in blood pressure elicited by nitroprusside and thiocyanate.
The drug seems to have no definite effect over a period of months on renal blood flow or filtration rate. It is very difficult to be sure whether nitroprusside aided in healing the lesions of malignant hypertension in the eyegrounds. In two patients they cleared during treatment with nitroprusside. It certainly does not prevent the appearance of heart failure, myocardial infarction, or stroke, although it might retard their appearance.
Since hydralazine and hexamethonium given to normal anesthetized dogs augment the depressor action of nitroprusside given intravenously, we tried a combination of the drugs in patients. We have been unable to prove any true synergism when the combinations were given by mouth. with that of the hypertensives, the latter seem much more sensitive to the hypotensive effect of nitroprusside. The effect on responsiveness to chronic oral hydralazine treatment (table 5) was investigated in five; tests were done before and during the administration of therapeutic amounts (400 to 800 mg. per day) of this drug. Three patients showed reproducible increases in sensitivity to intravenous nitroprusside while taking hydralazine in a dose which was not of itself depressor.
CARI)I(O)VASCULAR ACTIONS OF S(O)DIIIM

Treatment of Hypertensive Encephalopathy
The hypotensive effects of intravenous nitroprusside have been used in the control of some of the complications of hypertensive vascular disease (table 6) . For this purpose constant infusions were continued for periods ranging from five hours to fourteen days ( fig. 2) . Prolonged decreases of arterial pressure could be maintained by regulation of the rate of infusion; tolerance to nitroprusside was observed in only one patient; this was overcome by giving intravenously a dose of hexamethonium which did not of itself decrease arterial pressure. The prolonged administration of nitroprusside was without deleterious effect; in one patient who had severe renal insufficiency, treatment was discontinued after 14 days because the serum thiocyanate level had risen to 12.6 mg. per 100 cc. Administration from a constant infusion pump enables excellent control of blood pressure at stable levels for many hours once an optimum rate of infusion has been established.
The effectiveness of nitroprusside is best exemplified by its use in five bouts of hypertensive encephalopathy in one patient. The following is a brief description of one of these episodes.
Case history: I. G., a 29 year old colored woman with severe hypertensive vascular disease had sudden onset of generalized headache which awoke her from a sound sleep. She was given 0.25 Gm. sodium amytal intramuscularly without effect. The headache became increasingly severe; restlessness and drowsiness developed. Upon examination she appeared acutely ill; her face was very pale.
Although drowsy she responded fairly well to questioning. A neurological examination revealed no localizing signs and the blood pressure was 290/170. On the basis of these findings it seemed that she had rapidly progressing hypertensive encephalopathy. Several hours previously she had received 100 mg. of hexamethonium intravenously without change in supine blood pressure readings and only slight postural hypotension which had disappeared within a few hours. Accordingly, intravenous nitroprusside was given. As a solution of 100 micrograms per ml. was being prepared she became semicomatose; the restlessness increased. Just as the venipuncture was made she ceased to respond to painful stimuli. The nitroprusside was given rapidly at approximately 300 micrograms per minute; within one minute the blood pressure had fallen to 120/70 so the infusion rate was decreased to 100 micrograms per minute. As the blood pressure fell the restlessness disappeared promptly. Within 15 to 20 minutes after start of the infusion, she began to respond to painful stimuli; the level of consciousness gradually improved and within one hour she was responding to questioning but was drowsy and complained of a severe headache. With only occasional and minor adjustments, the infusion rate was maintained at 100 micrograms per minute for a period of 30 hours and the blood pressure ranged from 200/100 to 140/90. The headache and drowsiness continued for several hours but slowly disappeared. She became alert and cheerful about 24 hours after the beginning of the infusion; the nitroprusside infusion rate was gradually decreased during the next few hours; the blood pressure rose and when the infusion was discontinued, 
DISCUSSION
Nitroprusside has been shown to decompose in contact with tissue with liberation of cyanogen. This is probably dependent on the interaction of the sulfhydryl compounds in body fluids with the nitroprusside ion. But this reaction is so slow as to preclude its being responsible for the hypotensive effect. The intact nitroprusside molecule itself must be the cause of the quick depression of arterial pressure when it is injected intravenously. Chronic administration by mouth has no such intense hypotensive action; rather its effect seems to be due to the increase in the thiocyanate level of the blood into which the cyanogen is converted. In hypertensive patients, the effects of nitroprusside and thiocyanate, given by mouth over periods of months, are indistinguishable.
Nitroprusside is an unusually powerful hypotensive agent acting in doses of 2 micrograms per kilogram in anesthetized dogs. Unanesthetized hypertensive patients required about 50 to 100 micrograms per minute to elicit sustained hypotension. The drug seems to act primarily on the vascular musculature relatively independently of the nervous system. Its depressor action is augmented in both dogs and patients by autonomic ganglion blocking agents such as tetraethylammonium chloride (TEAC) and hexamethonium, as well as moderately by such drugs as hydralazine and alstonine. We presume this is due chiefly to damping of the buffer reflexes.
The kidney blood vessels are responsive to nitroprusside. Nitroprusside infusions in normal dogs cause relatively more renal vasodilation than decrease in arterial pressure. In dogs with renal hypertension (produced by Page's method) somewhat larger doses elicit equivalent decreases in renal resistance and arterial pressure, which are often associated with decreased rate of glomerular filtration. In hypertensive patients renal vasodilatation is roughly proportional to the decrease in arterial pressure, and glomerular filtration is not disproportionately decreased by the fall in pressure.
Since the substance was so powerful in reduc-ing blood pressure when given intravenously, we have tested it carefully in both hypertensive dogs and man for its activity when given by mouth. Dogs with both experimental renal and neurogenic hypertension given large doses for periods up to six months failed to show an impressive effect on blood pressure. These animals proved surprisingly resistant to elevation of their blood thiocyanate level; much greater doses of both nitroprusside and thiocyanate were required than in hypertensive human beings. Rats given large amounts of nitroprusside for a year showed no tissue changes at autopsy.
Clinical trial of nitroprusside for periods up to two years demonstrated no superiority of nitroprusside over thiocyanate. In fact, they seem identical in both their therapeutic and toxic actions.
The results of sensitivity tests, using nitroprusside infusions, suggest that hypertensive patients are more sensitive than the two normotensive subjects we have studied. The sensitivity to intravenous nitroprusside could be increased by chronic administration of hydralazine or hexamethonium.
The drug proved to be of very considerable practical use in the treatment of patients with hypertensive encephalopathy. Both 3. Nitroprusside is moderately vasodilator in perfused kidneys of dogs and strongly dilator in perfused hind legs. In normal conscious dogs it caused slight increase in renal blood flow and decrease in vascular resistance with no effect on the maximal tubular excretory capacity for para-aminohippurate (TmPAH) OR the maximal tubular capacity for reabsorption of glucose (TmG), when infused intravenously. A dog with neurogenic hypertension in contrast with those with renal hypertension, exhibited large decreases in both arterial pressure and renal resistance. 4 . Moderately depressor doses induce renal vasodilatation in hypertensive patients which is roughly equivalent to the decrease of pressure. It does not increase renal blood flow appreciably nor decrease glomerular filtration conspicuously. 5 . Chronic oral administration of nitroprusside to renal and neurogenic hypertensive dogs produced no significant change in arterial pressure. Enough sodium thiocyanate to give thiocyanate blood levels comparable to those obtained with nitroprusside was also ineffective. Nitroprusside produced no tissue changes in rats given 1 mg. per kilogram intravenously five times a week for a year. 
